Pharmaceutical

Datopotamab deruxtecan by Daiichi Sankyo for Epithelial Ovarian Cancer: Likelihood of Approval

Datopotamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Epithelial Ovarian Cancer.

Apr 23, 2024 - 00:00
Datopotamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Epithelial Ovarian Cancer.
Read the original article

Tags:

Previous Article

Datopotamab deruxtecan by Daiichi Sankyo for Head And Neck Squamous Cell Carcino...

Next Article

Datopotamab deruxtecan by Daiichi Sankyo for Peritoneal Cancer: Likelihood of Ap...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Amazon expands telehealth clinic nationwide

Amazon expands telehealth clinic nationwide

Aug 1, 2023

Iovance’s PDUFA date for lifileucel pushed due to FDA backlog

Iovance’s PDUFA date for lifileucel pushed due to FDA b...

Sep 15, 2023

How did hiring in the Chinese pharma industry perform in Q2 2023

How did hiring in the Chinese pharma industry perform i...

Jul 29, 2023